10,700 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by Toth Financial Advisory Corp

Key Points

• Toth Financial Advisory Corp has made a new investment of approximately $296,000 in Kiniksa Pharmaceuticals International, plc by acquiring 10,700 shares during the 2nd quarter.
• Several institutional investors have recently increased their holdings in Kiniksa Pharmaceuticals, with ProShare Advisors LLC leading with a 35.5% boost to its stake.
• Analysts have issued positive ratings and raised price targets for Kiniksa, with Wells Fargo increasing their target from $30.00 to $42.00 and Jefferies raising it further to $54.00.

Toth Financial Advisory Corp purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,700 shares of the company's stock, valued at approximately $296,000.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $33,000. Asset Management One Co. Ltd. acquired a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $61,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock traded up $0.66 during trading hours on Monday, reaching $36.08. 267,055 shares of the stock were exchanged, compared to its average volume of 393,581. The firm's 50 day moving average is $32.77 and its 200 day moving average is $27.80. The stock has a market cap of $2.67 billion, a P/E ratio of 902.23 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $37.34.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on KNSA shares. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Finally, Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average target price of $41.17.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 29,325 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the sale, the insider owned 57,403 shares of the company's stock, valued at approximately $1,868,467.65. This trade represents a 33.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the sale, the chief operating officer owned 49,915 shares in the company, valued at approximately $1,657,178. This represents a 73.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 561,371 shares of company stock valued at $18,825,009 in the last three months. 53.48% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.